October 1, 2023 - In a special feature by Drug Development and Delivery, Dr. Anquetil, PHD, MBA, CEO and Founder of Portal Instruments, explains how PRIME not only prioritizes patient comfort and compliance but also aligns with environmental sustainability.
Portal Instruments: PFS Addresses Variety of Injection Challenges
October 1, 2023 - Portal Instruments, led by Dr. Patrick Anquetil, PHD, MBA, CEO and Founder, is setting a new standard in drug delivery with its groundbreaking PRIME device. In a special feature, Dr. Anquetil explains how PRIME not only prioritizes patient comfort and compliance but also aligns with environmental sustainability. This needle-free injection device offers a revolutionary approach to high viscosity therapies, addressing challenges such as needle fear, injection pain, and the need for real-time tracking and reminders.
Read the full Drug Development and Delivery special feature here.
May 10, 2022 - Portal Instruments has been featured in Fierce Pharma. "Gerresheimer invests in Portal's needle-free drug delivery, teeing Takeda partner up to advance tech", showcases Gerresheimer's agreement with Portal to support the development of the needle-free drug delivery platform.
November 2024, Cambridge, MA – Seasoned drug delivery executive, Steven Kaufman, to join Portal Instruments as their Chief Commercial Officer. Prior to joining Portal Instruments in November 2024, Steven held executive positions at Stevanato Group, Bespak and SHL Medical.
Portal Instrument's CEO, Dr. Patrick Anquetil, shares insights on reducing healthcare waste through reusable autoinjectors in a compelling OnDrug Delivery interview, "A Sustainable Future for Self-Injection with Connected, Reusable Autoinjectors."
Please fill out the details below and we will get back to you shortly.